Unlocking new potential: Rationale and evidence for dual EZH2/AR inhibition in mCRPC

from touchPODCAST · host touchpodcast

touchTALKS for touchONCOLOGY Listen to Dr Teresa Alonso-Gordoa, as she evaluates the latest data on dual EZH2/AR inhibition in mCRPC and explores how emerging evidence could influence clinical decision-making in the future. The expert Dr. Teresa Alonso-Gordoa - Hospital Universitario Ramón y Cajal, Madrid, Spain This touchPODCAST is for HCPs outside of the UK only. This activity is funded by an independent medical education grant from Pfizer. This activity is provided by touchIME. touchIME is an EBAC® accredited provider. For further information visit our website: www.touchONCOLOGY.com

Episode metadata supplied by the publisher feed · Published Apr 28, 2026

Embed this episode

Attribution link and audio player

Ready to play

Unlocking new potential: Rationale and evidence for dual EZH2/AR inhibition in mCRPC

0:00 30:52

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of touchPODCAST?

This episode is 30 minutes long.

When was this touchPODCAST episode published?

This episode was published on April 28, 2026.

Can I download this touchPODCAST episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!